Mai Capital Management Autolus Therapeutics PLC Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
A detailed history of Mai Capital Management transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Mai Capital Management holds 33,866 shares of AUTL stock, worth $79,246. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,866
Previous 328,326
89.69%
Holding current value
$79,246
Previous $771,000
93.26%
% of portfolio
0.0%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding AUTL
# of Institutions
98Shares Held
163MCall Options Held
0Put Options Held
88.3K-
Wellington Management Group LLP Boston, MA27.1MShares$63.4 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$47.9 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$41.8 Million0.97% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$38.9 Million97.79% of portfolio
-
Armistice Capital, LLC New York, NY11MShares$25.7 Million0.26% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $213M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...